Joint Implementation Plan for the EU MDR

by | Mar 30, 2020 | EU, EU MDR, OQA, QMS, Quality Systems, Requirements

The European Medical Device Coordination Group published a joint implementation plan ahead of the May 2020 deadline for the full implementation of the EU MDR. The plan addresses the concern that the implementation of the MDR has proven to be a challenging task for the medical device industry, European member states, and the EU commission and further mentions that the involved stakeholders must step up their efforts to achieve the May 2020 deadline.1

The joint implementation plan sets the priorities and contingency actions that are essential to have a  fully operational EU MDR compliant system in place by May 2020. The plan prioritizes the following elements pertaining to the medical device regulations:

EUDAMED

Roll out of the EUDAMED database has been delayed, however, the plan endorses that a delay in implementation of the database should not prevent the timely application of the MDR. The EU Commission is prioritizing the release of the actor module of the EUDAMED by 26th May 2020 and gradually releasing the other modules with a target completion date set in May 2022.1

Placing safe devices on the market after May 26, 2020

The biggest challenge that the industry will have to face with the implementation of the MDR is a shortage of medical devices due to the limited number of notified bodies available to certify medical devices, as well as companies that are pulling out their devices off the market. Though 11 notified bodies are accredited by the EU to carry out conformity assessments, the concerns remain on the capacity of the notified bodies.1

Switzerland’s exit from the EU

If the EU-Switzerland Mutual Recognition Agreement is not updated by 26 May 2020, then the conformity certificates issued by the Swiss notified bodies will become invalid. To place a medical device in the EU market, the manufactures will have to transfer their certificates to an EU based notified body. In addition to that, Switzerland will be considered a third country and Swiss-based manufacturers will need an authorized representative in the EU.1

Clarification regarding clinical evaluations and expert panels

With the stringent requirements established in the MDR for clinical data, clinical evaluation, post-market clinical studies, manufacturers are in need of clarifications to understand what an adequate approach would be to apply for their products. The work to set up an expert panel to evaluate the clinical requirements of the regulations as well as making guidance documents available to the industry to support in implementing these requirements is advancing.1

Monitoring

The EU Commission intends to request regular updates from the industry and the NBs to monitor the implementation and the transition progress ahead of May 2020 and beyond.1

These priorities have been identified based on the objectives of public health, patient safety, and transparency. The EU Commission’s efforts to work on the priorities mentioned above is ongoing. It is worth noting that focusing on a limited set of agreed-upon priorities could result in temporarily fewer resources being placed into other areas. However, patient access to safe and efficient medical devices will be at the forefront of all the implementation efforts.1

Need help with your EU MDR transition. Call us today at 248-987-4497 or email us at info@emmainternational.com to see how we can help.


1Medical Device Coordination Group (March 2020) retrieved on 03/17/2020 from https://ec.europa.eu/docsroom/documents/40286?locale=en

 

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

The End of the COVID-19 Public Health Emergency

The End of the COVID-19 Public Health Emergency

After over 3 years, the COVID-19 Public Health Emergency (PHE) will end on May 11, 2023, the Biden Administration announced last week.1After 3.5 years of the modified policy to allow for amore efficient path for COVID-19-related medical products to get to market, this begs the question of how it will impact the MedTech world.
Process Validation

Process Validation

All right, you have just gotten all of your paperwork together, submitted the right forms to the right people, set up your factory, hired and trained your staff; now it’s time to make the medical devices. The regulatory nonsense is over and done, right?
The Role of Management in Product Quality

The Role of Management in Product Quality

Depending on the factory, some production employees may find it surprising that management has an important role to play in a quality system.  21 CFR 820.20 mandates that “Management with executive responsibility shall establish objectives for, and commitment to, quality”.[1]  The Federal Government expects that management takes an active interest in improving the output of their company, at least in the case of medical device manufacturers.

Ready to learn more about working with us?

Pin It on Pinterest

Share This